Liuzijue as an effective rehabilitation exercise for chronic obstructive pulmonary disease: a systematic review and meta-analysis
Mo-han Fan , Robin W. M. Vernooij , Zhan-ju Fu , Bao-yi Shao , Jia-qi Li , Hua-xi Yang , Er-yu Wang , Lin-jing Qiu , Lei Wang , Ying Zhang
Evidence-Based Chinese Medicine and Technology Assessment ›› 2026, Vol. 2 ›› Issue (2) : 9570032
Introduction Liuzijue (LZJ), a traditional Chinese exercise, may improve quality of life and pulmonary function in patients with chronic obstructive pulmonary disease (COPD), but evidence for its efficacy and assessment of any subgroup differences remains insufficient. This systematic review of randomized controlled trials (RCTs) evaluated LZJ’s effects on patient outcomes. Methods The Cochrane Library, Web of Science, PubMed, and three Chinese databases were systematically searched from their inception until December 31, 2025. Rigorous screening, assessment of risk of bias, and data extraction were performed in duplicate by two reviewers. A random-effects model with predefined subgroup analyses was used. Statistical significance was set at P < 0.1, and subgroup effect credibility was assessed via a five-criteria checklist. A GRADE evidence profile was established to assess the certainty of evidence. Results We included 24 eligible RCTs comprising 1467 patients. Compared with usual care, the standardized mean difference (SMD) on quality of life in the LZJ group was −0.84 (95% confidence interval [CI]: −1.20, −0.47, P < 0.00001). There were statistical differences for LZJ group for forced expiratory volume in 1 second (FEV1) (mean difference [MD] = 0.28, 95% CI: 0.13, 0.42, P = 0.0002), FEV1% (MD = 5.19, 95% CI: 2.76, 7.62, P < 0.0001), FEV1/forced vital capacity (FVC)% (MD = 6.97, 95% CI: 1.19, 12.75, P = 0.02), and 6-minute walk distance (m) (MD = 33.64, 95% CI: 22.17, 45.10, P < 0.00001). However, no differences were found for FVC (MD = 0.18, 95% CI: −0.06, 0.42, P = 0.14). The certainty of the evidence was low to very low because of the risk of bias, inconsistency, or indirectness. Conclusion Regularly performing LZJ is beneficial for COPD recovery, based on evidence of low to very low certainty. Rigorously designed RCTs that address patient outcomes with longer follow-up periods are required.
Liuzijue / chronic obstructive pulmonary disease / traditional Chinese medicine / randomized controlled trials / systematic review / meta-analysisGRADE
| [1] |
|
| [2] |
Chronic Obstructive Pulmonary Disease Group of Respiratory Branch of Chinese Geriatric Society. Clinical practice guideline for diagnosis and management of chronic obstructive pulmonary disease in elderly patients. Chin J Tuberc Respir Dis. 2020; 43(2):100-119. |
| [3] |
|
| [4] |
Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chinese Medical Association. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2007). Chin J Intern Med. 2007; 46(3):254-261. |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Introduction & history of Liu Zi Jue. Chinese Health Qigong Association in YouTubeJP Web site. https://youtu.be/_6FZ1BtxrUA 2020.4.16. Accessed May 8, 2025. |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chinese Medical Association. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2013). Chin J Tubercul Resp Dis. 2013; 36(4):255-264. |
| [15] |
Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chinese Medical Association, Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician, Chinese Medicine Doctor Association. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021). Chin J Tubercul Resp Dis. 2021; 44(3):170-205. |
| [16] |
|
| [17] |
Cochrane Web site. About risk of bias 2 (RoB 2). https://www.cochrane.org/learn/courses-and-resources/cochrane-methodology/risk-bias/about-risk-bias-2-rob-2. Accessed April 1, 2025. |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
/
| 〈 |
|
〉 |